Urinary tract infection

Volurine Utilizes D-Mannose to Safely Prevent UTIs

Retrieved on: 
Wednesday, January 31, 2024
Mannose, Bacteria, Heart, System, Urinary tract infection, Urination, Escherichia coli, Risk, Infection, UTI, Health, Genetically modified bacteria, Woman, Dietary supplement

FORT LAUDERDALE, Fla., Jan. 31, 2024 /PRNewswire/ -- Urinary tract infections or UTIs are a common bacterial infection. Health brand SYNEVIT®'s natural supplement Volurine helps manage UTIs quickly. Its key ingredient is D-mannose, which has been shown to be effective in managing one of the most common bacterial culprits in UTIs.

Key Points: 
  • Health brand SYNEVIT®'s natural supplement Volurine helps manage UTIs quickly.
  • Its key ingredient is D-mannose, which has been shown to be effective in managing one of the most common bacterial culprits in UTIs.
  • One of these is D-mannose, a natural simple sugar that functions as the key ingredient in SYENVIT®'s UTI supplement Volurine .
  • It is becoming a popular natural alternative that is a safe, effective way to prevent UTIs without the need to wait for the signs of a painful infection to appear.

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 January 2024

Retrieved on: 
Sunday, February 4, 2024
Civil service commission, Pneumonia, Febrile neutropenia, Eli Lilly, Triprolidine, International, Bacteria, Schizophrenia, Myelopathy, Incidence, ALD, Cefepime, Allergic rhinitis, Nasal congestion, Neutrophil, Agency, COMP, Fever, HAP, EEIG, Headache, Static pressure, Medicine, Committee, Conditional, Spinal cord, Hospital-acquired pneumonia, PTC, Neutropenia, Public, CHMP, European, AMD, Patient, Diagnosis, Marketing, RCVS, European Commission, Brain, Disease, Infection, Inflammation, Male, PRES, PRAC, Pain, Pyelonephritis, Urinary tract infection, VAP, Ageing, EMA, Geographic atrophy, Adrenoleukodystrophy, Therapy, News, INN, Duchenne muscular dystrophy, Common, Fungal infection, Vaccine

Three new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended three medicines for approval at its January 2024 meeting.The committee recommended…, Positive recommendations on new medicines, Exblifep International non-proprietary name (INN)cefepime / enmetazobactam Marketing-authorisation applicantAdvanz Pharma LimitedTherapeutic indicationTreatment of: 1)…, Ryzneuta INNefbemalenograstim alfaMarketing-authorisation applicantEvive Biotechnology Ireland LimitedTherapeutic indicationReduction in the duration of neutropenia and…, Positive recommendations on new generic medicines, Niapelf INNpaliperidoneMarketing-authorisation applicantNeuraxpharm Pharmaceuticals S.L.Therapeutic indicationTreatment of schizophreniaMore informationNiapelf: Pending…, Negative recommendations on new medicines, Nezglyal INNleriglitazoneMarketing-authorisation applicantMinoryx Therapeutics S.L.Therapeutic indicationTreatment of cerebral progression and myelopathy in male…, Syfovre INNpegcetacoplanMarketing-authorisation applicantApellis Netherlands B.V.Therapeutic indicationTreatment of geographic atrophy (GA) secondary to age-related…, Positive recommendations on extensions of indications, Abecma INNidecabtagene vicleucel Marketing-authorisation holderBristol-Myers Squibb Pharma EEIGMore informationAbecma: Pending EC decision, Prevenar 20 (previously Apexxnar) Common namepneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)Marketing-authorisation holderPfizer Europe MA EEIGMore…, Aspaveli INNpegcetacoplanMarketing-authorisation holderSwedish Orphan Biovitrum AB (publ)More informationAspaveli: Pending EC decision, Retsevmo INNselpercatinibMarketing-authorisation holderEli Lilly Nederland B.V.More informationRetsevmo: Pending EC decision, Outcome of re-examination of recommendation on non-renewal of Conditional Marketing Authorisation, Translarna INNataluren Marketing-authorisation holderPTC Therapeutics International LimitedNewsEMA confirms recommendation for non-renewal of authorisation of Duchenne…, Outcome of referral, Pseudoephedrine Marketing-authorisation holderVarious companiesMore informationPseudoephedrine-containing medicinal products, Re-examination of conclusion of referral, Synapse Labs Pvt.

Key Points: 
  • Three new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended three medicines for approval at its January 2024 meeting.The committee recommended…, Positive recommendations on new medicines, Exblifep International non-proprietary name (INN)cefepime / enmetazobactam Marketing-authorisation applicantAdvanz Pharma LimitedTherapeutic indicationTreatment of: 1)…, Ryzneuta INNefbemalenograstim alfaMarketing-authorisation applicantEvive Biotechnology Ireland LimitedTherapeutic indicationReduction in the duration of neutropenia and…, Positive recommendations on new generic medicines, Niapelf INNpaliperidoneMarketing-authorisation applicantNeuraxpharm Pharmaceuticals S.L.Therapeutic indicationTreatment of schizophreniaMore informationNiapelf: Pending…, Negative recommendations on new medicines, Nezglyal INNleriglitazoneMarketing-authorisation applicantMinoryx Therapeutics S.L.Therapeutic indicationTreatment of cerebral progression and myelopathy in male…, Syfovre INNpegcetacoplanMarketing-authorisation applicantApellis Netherlands B.V.Therapeutic indicationTreatment of geographic atrophy (GA) secondary to age-related…, Positive recommendations on extensions of indications, Abecma INNidecabtagene vicleucel Marketing-authorisation holderBristol-Myers Squibb Pharma EEIGMore informationAbecma: Pending EC decision, Prevenar 20 (previously Apexxnar) Common namepneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)Marketing-authorisation holderPfizer Europe MA EEIGMore…, Aspaveli INNpegcetacoplanMarketing-authorisation holderSwedish Orphan Biovitrum AB (publ)More informationAspaveli: Pending EC decision, Retsevmo INNselpercatinibMarketing-authorisation holderEli Lilly Nederland B.V.More informationRetsevmo: Pending EC decision, Outcome of re-examination of recommendation on non-renewal of Conditional Marketing Authorisation, Translarna INNataluren Marketing-authorisation holderPTC Therapeutics International LimitedNewsEMA confirms recommendation for non-renewal of authorisation of Duchenne…, Outcome of referral, Pseudoephedrine Marketing-authorisation holderVarious companiesMore informationPseudoephedrine-containing medicinal products, Re-examination of conclusion of referral, Synapse Labs Pvt.
  • Ltd. Marketing-authorisation holderVarious companiesMore informationSynapse

EQS-News: G.ST Antivirals reports positive Phase I trial results for 2-Deoxy-D-glucose against upper respiratory infections

Retrieved on: 
Tuesday, January 30, 2024
Entrepreneurship, Patient, Șaeș, Infection, Drug resistance, CSO, Virus, FFG, Safety, Aes, Urinary tract infection, SAD, Reproduction, Auxiliaries, EUR, Recreational vehicle, Hospital, Glycolysis, Parent, Phase, Metabolism, Pharmacokinetics, Pharmaceutical industry

Results of the Phase I trial demonstrated that an intranasal administration of 2-DG is safe, well tolerated and does not lead to any serious adverse events (SAEs).

Key Points: 
  • Results of the Phase I trial demonstrated that an intranasal administration of 2-DG is safe, well tolerated and does not lead to any serious adverse events (SAEs).
  • Alongside these clinical results, the company has raised funds totalling over EUR 6 million to complete the Phase II clinical trial.
  • “The results of the Phase I trial confirm the safety of our innovative approach of using 2-DG to treat respiratory infections.
  • “While viral infections of the upper respiratory tract are ubiquitous, they are currently insufficiently treated, and RVs are responsible for most of these infections.

Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis

Retrieved on: 
Thursday, January 25, 2024
Cystic fibrosis, Patient, Pancreas, Research, Cystic Fibrosis Foundation, Urinary tract infection, CFTR, DSM-IV codes, Nonsense, Mutation, Disease, Mucus, Vaccine

Funding from the CF Foundation will allow Prime Medicine to progress two distinct strategies for applying Prime Editing to treat CF: hotspot editing and PASSIGE™ (Prime Assisted Site Specific Integrase Gene Editing).

Key Points: 
  • Funding from the CF Foundation will allow Prime Medicine to progress two distinct strategies for applying Prime Editing to treat CF: hotspot editing and PASSIGE™ (Prime Assisted Site Specific Integrase Gene Editing).
  • Through hotspot editing, the Company aims to address multiple mutations at mutational hotspots with a small number of Prime Editors.
  • Prime Medicine has begun preclinical research to use hotspot Prime Editors to correct the G542X nonsense CFTR mutation, and plans to extend this work to develop hotspot Prime Editors for other clusters of CFTR mutations.
  • Prime Medicine is eligible for an additional $6 million upon achieving certain preclinical milestones, with up to $3 million in supplementary funding upon mutual agreement.

Locus Biosciences Announces $23.9 Million in Funding from BARDA to Support First Phase 2 Trial of CRISPR-engineered Bacteriophage Therapy

Retrieved on: 
Tuesday, January 23, 2024
Locus Biosciences, Development, Escherichia coli, World Health Organization, Patient, MDR, Part, Genetically modified bacteria, CRISPR, Partnership, UTI, Administration, Infection, Public, Recurrence, Food, Part Two, Urinary tract infection, Human services, Marketing, Clinical trial, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Locus Biosciences, Inc. (“Locus”), a clinical-stage biotechnology company developing a new class of precision engineered bacteriophage treatments for a diverse set of bacterial diseases, today announced the release of $23.9 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to continue the development of Locus’ CRISPR-enhanced bacteriophage therapy, LBP-EC01, for treating urinary tract infections (UTIs) caused by drug-resistant Escherichia coli (E. coli) based on positive results from a Phase 2a clinical trial.

Key Points: 
  • Approximately 80% of these are caused by E. coli, often including difficult-to-treat strains that are resistant to commonly used antibiotics.
  • The funding will be used to advance LBP-EC01 into the blinded, placebo-controlled, Part 2 of the ELIMINATE Phase 2 trial.
  • In 2020, Locus and BARDA announced an agreement to co-fund development of LBP-EC01.
  • The award announced today brings the amount released under the contract to $48.9 million.

Electromed, Inc. Announces Partnership to Expand SmartVest Access to Veterans, Federal Employees, and Native American Communities

Retrieved on: 
Monday, January 29, 2024
White House, Federal Government, Other Health, Healthcare Reform, Small Business, General Health, Professional Services, Medical Devices, Defense, Public Policy, Government, Transport, Native American, Veterans, Logistics, Supply Chain Management, Consumer, Health, Medical Supplies, Patient, SDVOSB, Health care, Indian Health Service, Partnership, Federal, Risk, Quality of life, Veteran, Urinary tract infection, Atmosphere, Native Americans, Mucus

Electromed, Inc. (NYSE American: ELMD) today announced it has entered into a distribution agreement with Marathon Medical Corp., a medical supply distribution company and service-disabled veteran-owned small business (SDVOSB).

Key Points: 
  • Electromed, Inc. (NYSE American: ELMD) today announced it has entered into a distribution agreement with Marathon Medical Corp., a medical supply distribution company and service-disabled veteran-owned small business (SDVOSB).
  • SmartVest® Airway Clearance System, which is designed for High Frequency Chest Wall Oscillation (“HFCWO”) therapy, a clinically proven therapy that helps clear the lungs of excess secretions, thereby reducing the risk of respiratory infections and hospitalizations for those suffering from a chronic lung condition.1 As a distribution partner, Marathon Medical focuses on providing medical products to Federal agencies including VA hospitals and clinics, Indian Health Service hospitals and clinics, and other Federal agencies.
  • “This partnership will improve the ordering process for all government facilities allowing easier access to our products, so veterans can breathe easier and live better,” said Jim Cunniff, President and Chief Executive Officer of Electromed.
  • The SmartVest Clearway system is indicated for use in patients managing non-cystic fibrosis bronchiectasis (NCFB) and other chronic pulmonary conditions.

InventHelp Inventor Develops New Female Incontinence Product (CHK-972)

Retrieved on: 
Wednesday, January 24, 2024
Woman, Urinary tract infection, Multimedia, Risk, Sale, Suite, Water, CNA, Feces

I wanted to protect myself from accidentally spreading or splashing feces onto my genital area," said an inventor from Round Lake, IL, "so I invented the Fanny Shield.

Key Points: 
  • I wanted to protect myself from accidentally spreading or splashing feces onto my genital area," said an inventor from Round Lake, IL, "so I invented the Fanny Shield.
  • My design can reduce the potential for toilet water or paper to spread feces to the female genitalia area.
  • The patent-pending Fanny Shield is a barrier protection product that would allow women to have a bowel movement without the risk of a urinary tract infection.
  • For more information, write Dep22-CHK-972, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext.

Global Urinary Tract Infection (UTI) Treatment Market is expected to Reach US$ 13,617.4 million by 2034, rising at a 1.9% CAGR- FMI Study

Retrieved on: 
Monday, January 22, 2024
Patient, Catheter, Research, Bladder cancer, UTI, Developed country, Risk, Urinary tract infection, Kidney, System, Cardiac catheterization, Drainage, Infection, FMI, Diagnosis, Prevalence, Medical imaging

NEWARK, Del., Jan. 22, 2024 /PRNewswire/ -- The Urinary Tract Infection (UTI) Treatment Market is estimated to be worth US$   11,244.0 million in 2024 and is projected to be valued at US$ 13,617.4 million in 2034. Between 2024 and 2034, the industry is expected to register a growth rate of 1.9%.

Key Points: 
  • Future Market Insights, Inc. (FMI) predicts a robust expansion of the urinary tract infection (UTI) treatment market, propelled by increasing infection rates, catheter use, and advancements in diagnosis and care.
  • Dive deeper into the intricate dynamics of this burgeoning market and uncover compelling stakeholder opportunities in our comprehensive FMI report.
  • NEWARK, Del., Jan. 22, 2024 /PRNewswire/ -- The Urinary Tract Infection (UTI) Treatment Market is estimated to be worth US$   11,244.0 million in 2024 and is projected to be valued at US$ 13,617.4 million in 2034.
  • Individuals using urinary catheters face an elevated risk of developing complicated urinary tract infections, driving the demand for UTI treatment .

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis

Retrieved on: 
Tuesday, January 16, 2024
Intellectual property, Death, Clostridioides difficile infection, Patient, Research, DSM-IV codes, Hospital, Health, Urine, Dark Enlightenment, Colitis, Tuberculosis, UTI, Clostridioides difficile, DCS, Tetracycline, QIDP, Risk, Infection, Cephalosporin, Pulmonary fibrosis, Sepsis, FDA, Priority review, Penicillin, New Drug Application, Pyelonephritis, Urinary tract infection, Literature, Contra, NMDA, CNS, Pharmaceutical industry

Receipt of QIDP designation confers Priority Review, and critically, five additional years of data-exclusivity to NRX-101's already strong Intellectual Property position.

Key Points: 
  • Receipt of QIDP designation confers Priority Review, and critically, five additional years of data-exclusivity to NRX-101's already strong Intellectual Property position.
  • The FDA also granted NRX-101 Fast Track designation for cUTI, which additionally allows for rolling submission of the Company's New Drug Application.
  • On the basis of this advance, NRx is seeking partners with active involvement in urology, infectious disease and/or women's health for commercialization of NRX-101.
  • NRx thanks the US FDA for its rapid award of QIDP designation for cUTI and pyelonephritis.

American Urological Association Announces 2024 Innovation Nexus Showcase Selections

Retrieved on: 
Wednesday, January 10, 2024
Nexus, Woman, Patient, Fertility, American Urological Association, Trauma, Therapy, Prostate cancer, Artificial intelligence, Bladder cancer, Urology, Showcase, Cystoscopy, Funding of science, FACS, University, Surgery, Incontinence, Carboxypeptidase, Hyperoxaluria, Conference, Urinary tract infection, Information technology, Urethra, Patient safety, AUA, Medical imaging

Baltimore, Jan. 10, 2024 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) is pleased to announce the ten companies chosen through a rigorous and highly competitive selection process for the second annual Innovation Nexus Showcase.

Key Points: 
  • Baltimore, Jan. 10, 2024 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) is pleased to announce the ten companies chosen through a rigorous and highly competitive selection process for the second annual Innovation Nexus Showcase.
  • Innovation Nexus is a long-term commitment by the AUA to sustain a urology incubator to advance discoveries with key stakeholders to benefit urologic patient care.
  • As part of the multi-faceted program, the AUA will host an annual Innovation Nexus Conference, with the second event being held on May 2 in San Antonio, TX, before the AUA Annual Meeting.
  • For more information on the Showcase and to register to attend the May 2 event, please visit: https://auanexus.org/